GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China SXT Pharmaceuticals Inc (NAS:SXTC) » Definitions » Return-on-Tangible-Asset

China SXT Pharmaceuticals (China SXT Pharmaceuticals) Return-on-Tangible-Asset : -87.96% (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is China SXT Pharmaceuticals Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. China SXT Pharmaceuticals's annualized Net Income for the quarter that ended in Sep. 2023 was $-19.39 Mil. China SXT Pharmaceuticals's average total tangible assets for the quarter that ended in Sep. 2023 was $22.05 Mil. Therefore, China SXT Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2023 was -87.96%.

The historical rank and industry rank for China SXT Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:

SXTC' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -64.02   Med: -9.79   Max: 21.99
Current: -64.02

During the past 7 years, China SXT Pharmaceuticals's highest Return-on-Tangible-Asset was 21.99%. The lowest was -64.02%. And the median was -9.79%.

SXTC's Return-on-Tangible-Asset is ranked worse than
85.89% of 1084 companies
in the Drug Manufacturers industry
Industry Median: 1.745 vs SXTC: -64.02

China SXT Pharmaceuticals Return-on-Tangible-Asset Historical Data

The historical data trend for China SXT Pharmaceuticals's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China SXT Pharmaceuticals Return-on-Tangible-Asset Chart

China SXT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Return-on-Tangible-Asset
Get a 7-Day Free Trial 12.31 -52.68 -9.79 -16.87 -18.83

China SXT Pharmaceuticals Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.65 -18.84 -10.74 -34.37 -87.96

Competitive Comparison of China SXT Pharmaceuticals's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China SXT Pharmaceuticals's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where China SXT Pharmaceuticals's Return-on-Tangible-Asset falls into.



China SXT Pharmaceuticals Return-on-Tangible-Asset Calculation

China SXT Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Mar. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=-5.935/( (33.507+29.526)/ 2 )
=-5.935/31.5165
=-18.83 %

China SXT Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Mar. 2023 )(Q: Sep. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Mar. 2023 )(Q: Sep. 2023 )
=-19.392/( (29.526+14.565)/ 2 )
=-19.392/22.0455
=-87.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Sep. 2023) net income data.


China SXT Pharmaceuticals  (NAS:SXTC) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


China SXT Pharmaceuticals Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of China SXT Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


China SXT Pharmaceuticals (China SXT Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, Advanced TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates a majority of its revenue from the People's Republic of China.

China SXT Pharmaceuticals (China SXT Pharmaceuticals) Headlines

From GuruFocus

China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split

By GuruFocusNews GuruFocusNews 07-07-2022